Business
genedrive plc (GDR): First commercial sales in ...
genedrive plc (GDR): First commercial sales in ....
About this update from Genedrive Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats08-Apr-2019 / 10:53 GMT/BST\nHardman & Co Research: First commercial sales in new focus area: bio-threats\n\ngenedrive plc (GDR) is a commercial-stage company focused on point-of-care (PoC) molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis of infectious diseases. Rapid analysis of patient samples greatly aids clinical and public health decision-making, particularly in remote areas of developing countries. Strategic progress in 2018 generated the first product sales in hepatitis C and in 1H'19 has delivered the first product sales in the Bio-threat market to the US Department of Defense (DoD). Please click here for the full report:\n\nhttps://www.hardmanandco.com/research/corporate-research/first-commercial-sales-in-new-focus-area-bio-threats/\n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dorothea Hill+44 20 7194 7628\n [email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur research is provided for the use of the professional invest...